NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
NIH (NCCIH) R33 funding for early-phase clinical trials of natural products (botanicals, dietary supplements, probiotics) to confirm target engagement and inform whether further clinical research i…
- Deadline
- Nov 13, 2026
- Posted
- Dec 2, 2024
- Award amount
- Up to $1,050,000
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Nov 13, 2026 so you have time to apply.
In plain English
NIH (NCCIH) R33 funding for early-phase clinical trials of natural products (botanicals, dietary supplements, probiotics) to confirm target engagement and inform whether further clinical research is warranted. Intended for research institutions; foreign organizations are not eligible. The listed maximum is about $1,050,000. It will not support efficacy or effectiveness trials and requires strong preliminary data, making it narrow research-only funding.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
About this grant
This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This NOFO will not support efficacy or effectiveness trials, nor will
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Metastasis Research Network (U54 Clinical Trial Not Allowed)
National Institutes of Health · Up to $1.3M · Due Sep 25, 2026
Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)
National Institutes of Health · Up to $1.5M · Due Sep 30, 2026
Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)
National Institutes of Health · Up to $2.2M · Due Sep 30, 2026
Limited Competition: Intellectual and Developmental Disabilities Research Centers 2027 (P50 Clinical Trial Optional)
National Institutes of Health · Up to $800K · Due Oct 2, 2026
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · $50K–$600K · Due Oct 19, 2026
Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
National Institutes of Health · Amount varies · Due in 17 days
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.